Molex to Acquire Vectura Group From Philip Morris International (PMI)

Philip Morris International to Acquire Vectura Group

July 9, 2021

Healthcare Services

Philip Morris International (PMI) announced it has agreed to an all-cash, recommended offer to acquire Vectura Group plc for an enterprise value of GBP 852 million (approximately USD 1.2 billion). The deal is expected to close in the second half of 2021, subject to shareholder and regulatory approvals.

Philip Morris International Acquires Fertin Pharma from EQT Private Equity

July 1, 2021

Pharmaceuticals

Philip Morris International has agreed to acquire Fertin Pharma, a Denmark-headquartered specialist CDMO in oral and intra-oral delivery technologies, from EQT Private Equity for a headline enterprise value of DKK 5.1 billion. Fertin Pharma — which operates sites in Denmark, Canada and India and employs more than 860 people — will strengthen PMI's smoke-free and beyond-nicotine product capabilities; the transaction is subject to customary approvals.

Molex Agrees to Acquire Smiths Interconnect to Expand Aerospace and Medtech Connectivity

October 16, 2025

Industrial Services

Molex announced it has signed an agreement to acquire Smiths Interconnect, a subsidiary of the United Kingdom-based Smiths Group plc. The acquisition is expected to close in the first half of 2026, subject to regulatory approvals and customary closing conditions. The deal combines Molex’s aerospace and defense footprint and engineering capabilities with Smiths Interconnect’s high-reliability connectivity solutions for aerospace and defense, medical, and semiconductor test markets.

H.I.G. Capital Acquires BioVectra Inc.

November 4, 2019

Pharmaceuticals

H.I.G. Capital, through an affiliate, completed the acquisition of BioVectra Inc., a Canadian contract development and manufacturing organization (CDMO) specializing in active pharmaceutical ingredients (APIs), intermediates and biologics. The deal — a carve-out from Mallinckrodt — positions H.I.G. to support BioVectra's growth and further expand its manufacturing capabilities across Charlottetown, Prince Edward Island and Windsor, Nova Scotia.

Jabil Acquires Pharmaceutics International (Pii)

February 6, 2025

Pharmaceuticals

Jabil has acquired Pharmaceutics International (Pii), a Hunt Valley, Maryland-based contract development and manufacturing organization (CDMO) that provides aseptic filling, lyophilization and oral solid dose manufacturing. The all-cash transaction represents an exit for a consortium led by Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience Inc., and brings Pii’s ~300+ employees and four-site campus into Jabil’s Pharmaceutical Solutions offering to expand its drug development and manufacturing capabilities.

Novartis to Acquire MorphoSys in $2.9 Billion Deal

February 7, 2024

Pharmaceuticals

Novartis agreed to a voluntary public takeover offer to acquire MorphoSys AG for €68 per share, valuing the deal at about €2.7 billion (reported as $2.9 billion). The acquisition is intended to expand and complement Novartis’ oncology pipeline, including pelabresib (CPI-0610) and tulmimetostat (CPI-0209).